Compare EQBK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQBK | TBPH |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.8M | 1.0B |
| IPO Year | 2015 | N/A |
| Metric | EQBK | TBPH |
|---|---|---|
| Price | $46.10 | $19.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $50.50 | $27.80 |
| AVG Volume (30 Days) | 94.6K | ★ 362.2K |
| Earning Date | 01-21-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | 0.58 |
| Revenue | ★ $199,739,000.00 | $80,327,000.00 |
| Revenue This Year | $76.83 | $70.90 |
| Revenue Next Year | $4.61 | N/A |
| P/E Ratio | $37.50 | ★ $33.62 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $34.11 | $7.90 |
| 52 Week High | $50.07 | $21.03 |
| Indicator | EQBK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 49.33 |
| Support Level | $46.07 | $18.45 |
| Resistance Level | $48.25 | $19.71 |
| Average True Range (ATR) | 1.32 | 0.82 |
| MACD | -0.14 | -0.10 |
| Stochastic Oscillator | 31.80 | 46.28 |
Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).